Table 2

Characteristics of 20 patients from three centres

PatientAge/ SexTumour typeCheckpoint inhibitorFulfilled EULAR/ACR classification criteria*Unfulfilled criteriaAtypical featuresTreatment
Cleveland Clinic Foundation, Cleveland, Ohio, USA
163 MRCCNivolumabNo; five pointsAcute phase reactantsPrednisone 40 mg; tocilizumab 162 mg q2 weeks
269 MMelanomaIpilimumab/ nivolumabYes; six pointsSicca symptoms; antinuclear antibody 1:1280, anti-Sjogren’s-syndrome-related antigen A >8 IUPrednisone 30 mg
379 MMelanomaIpilimumab/ nivolumabYes; seven points†Sicca symptomsPrednisone 20 mg
457 MMelanomaPembrolizumabNo; three pointsAcute phase reactants; RF 35 IU/mL; knee involvementPrednisone 60 mg
560 MMelanomaPembrolizumabNo; three pointsRF 45 IU/mL; knee involvementPrednisone 60 mg
666 MMelanomaNivolumabYes; five pointsHand involvementPrednisone 20 mg; methotrexate
769 FRCCNivolumabYes; five pointsHand involvementPrednisone 10 mg; tocilizumab 162 mg q2 weeks
866 MRCCDurvalumab; tremilimumabYes; five pointsHand involvementPrednisone 20 mg
972 FRCCAvelumabYes; four pointsAcute phase reactants; hand and knee involvementPrednisone 20 mg
Johns Hopkins University, Baltimore, Maryland, USA
1066 MLung adenocarcinomaPembrolizumabNo; six pointsShoulder achingPrednisone 20 mg
1163 FPoorly differentiated carcinoma with squamous featuresDurvalumabYes; six pointsPrednisone 15 mg; hydroxychloroquine
1259 FMelanomaNivolumabYes; six pointsPrednisone 7.5 mg; bilateral trochanter injections
1376 MMerkle cell carcinomaNivolumab No; four points
Centre Hospitalier Universitaire, Bordeaux, France
1481 MMelanomaPembrolizumabNo; five pointsAcute phase reactants; knee involvementPrednisone 10 mg
1574 MMelanomaPembrolizumabYes; seven points†Prednisone 15 mg
1659 MMelanomaPembrolizumabNo; seven points†*Acute phase reactantsPrednisone 10 mg
1765 FNSCLCNivolumabNo; seven points†Acute phase reactantsPrednisone 15 mg
1863 MNSCLCNivolumabYes; six pointsResolved with NSAIDs aloneNSAIDs
1974 MRCCIpilimumab/ nivolumabYes; five pointsHand involvementPrednisone 10 mg
2077 FMelanomaPembrolizumabYes; six points†Hip painPrednisone 15 mg
  • All patients had complete reporting to allow application of the EULAR/ACR classification criteria.

  • *A score of four or more is needed for PMR classification without ultrasound, and a score of five or more if ultrasound is included.

  • †Met ultrasound criteria.

  • ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; NSAIDs, non-steroidal anti-inflammatory drugs; NSCLC, non-small cell lung cancer;PMR, polymyalgia rheumatica; RCC, renal cell carcinoma.